Eisai’s Lecanemab Hits All the High Points in Alzheimer’s Study

Eisai’s antiamyloid antibody lecanemab nearly eliminated amyloid brain plaques in 68 percent of Alzheimer’s (AD) patients, while modestly slowing decline on all four cognitive and functional measures in the CLARITY AD study, company executives and clinicians involved in the study said at the Clinical Trials on Alzheimer’s Disease annual meeting in San Francisco.
Source: Drug Industry Daily